AIM ImmunoTech logo
AIM ImmunoTech AIM
$ 0.11 -8.33%
report update icon

Quarterly report 2026-Q3
added 11-12-2026

AIM ImmunoTech Revenue | AIM

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue AIM ImmunoTech

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
88 K 170 K 202 K 141 K 135 K 163 K 140 K 367 K 437 K 92 K 133 K 197 K 150 K 213 K 161 K 27 K 111 K -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
437 K 27 K 172 K

Quarterly Revenue AIM ImmunoTech

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
22 K 26 K 22 K 21 K 26 K 25 K 16 K 45 K 35 K 50 K 40 K 65 K 46 K 42 K 49 K - 21 K 30 K 33 K - 33 K 23 K 28 K - 36 K 40 K 45 K - 61 K 29 K - - 38 K 33 K 56 K - 90 K 213 K 84 K - 22 K 15 K 39 K - 23 K 47 K 36 K 40 K 45 K 36 K 76 K 36 K 36 K 36 K 42 K 53 K 39 K 49 K 72 K 38 K 45 K 36 K 42 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
213 K 15 K 43.1 K

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
178 M - -15.15 % $ 60.3 M britainBritain
TFF Pharmaceuticals TFF Pharmaceuticals
TFFP
734 K - -60.05 % $ 125 K usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
22.9 M - -55.98 % $ 2.15 M usaUSA
Sage Therapeutics Sage Therapeutics
SAGE
41.2 M - - $ 527 M usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
160 M - - $ 121 M usaUSA
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
17.6 M - - $ 521 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
2.07 M $ 34.99 3.77 % $ 147 M usaUSA
Seelos Therapeutics Seelos Therapeutics
SEEL
2.2 M - -47.76 % $ 6.27 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
517 M - - - russiaRussia
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
163 M - - $ 2.18 B usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
2.07 M - - $ 1.41 B canadaCanada
Gritstone Oncology Gritstone Oncology
GRTS
16.3 M - 0.42 % $ 213 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
3.09 M - 17.91 % $ 11.1 M usaUSA
Titan Pharmaceuticals Titan Pharmaceuticals
TTNP
184 K - -3.76 % $ 3.47 M usaUSA
HOOKIPA Pharma HOOKIPA Pharma
HOOK
43.9 M - -6.92 % $ 79.4 M usaUSA
Otonomy Otonomy
OTIC
125 K - -1.96 % $ 4.68 M usaUSA
Ligand Pharmaceuticals Incorporated Ligand Pharmaceuticals Incorporated
LGND
268 M $ 286.96 0.01 % $ 5.55 B usaUSA
Фармсинтез Фармсинтез
LIFE
372 M - - - russiaRussia
Actinium Pharmaceuticals Actinium Pharmaceuticals
ATNM
90 K $ 1.04 -4.59 % $ 32.4 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
785 K - -24.12 % $ 1.56 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
325 K - - $ 26.5 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
32.6 M - - $ 401 M usaUSA
Histogen Histogen
HSTO
3.77 M - 31.6 % $ 2.12 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
41 K - - $ 169 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
36 M - -7.23 % $ 13 M usaUSA
Taro Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd.
TARO
573 M - - $ 1.62 B israelIsrael
Omeros Corporation Omeros Corporation
OMER
10.6 M $ 13.23 -5.71 % $ 840 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
1.18 M $ 0.94 -10.44 % $ 2.32 B israelIsrael
PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals
PHAS
10.8 M - 7.4 % $ 6.29 M usaUSA
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
7.44 M - - $ 958 M usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
509 M - - $ 8.14 B usaUSA
Horizon Therapeutics Public Limited Company Horizon Therapeutics Public Limited Company
HZNP
3.63 B - - $ 26.6 B irlandaIrlanda
Provention Bio Provention Bio
PRVB
12.9 M - - $ 2.37 B usaUSA
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
2.22 M - - $ 6.29 B usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
17 K $ 0.47 -24.53 % $ 305 K israelIsrael
iTeos Therapeutics iTeos Therapeutics
ITOS
35 M - - $ 411 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
405 K $ 1.44 -2.03 % $ 2.37 M israelIsrael
PolarityTE PolarityTE
PTE
814 K - -0.82 % $ 1.78 M usaUSA
Kronos Bio Kronos Bio
KRON
9.85 M - 1.49 % $ 50.8 M usaUSA
Cullinan Management Cullinan Management
CGEM
18.9 M $ 8.9 -1.93 % $ 536 M usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
3.51 M $ 39.15 0.57 % $ 3.52 B schweizSchweiz
Advaxis Advaxis
ADXS
13 K - -9.65 % $ 45.9 M usaUSA
Stoke Therapeutics Stoke Therapeutics
STOK
184 M $ 26.77 -0.59 % $ 1.59 B usaUSA
Trevena Trevena
TRVN
567 K - -46.58 % $ 31.8 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
9.75 M - -10.95 % $ 876 K usaUSA
Molecular Templates Molecular Templates
MTEM
18.8 M - -23.43 % $ 495 K usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
642 K $ 0.07 9.81 % $ 855 K usaUSA